Naonobu Sugiyama

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 1 paper. Top paper: “Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial”.

Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial

Annals of the Rheumatic Diseases(2022)10.1136/ard-2022-222543

N/A

4.5DataRank · unranked

163 citations

Kunihiro Yamaoka, Yi‐Hsing Chen, Deepak L. Bhatt, Levent M Gunay, Naonobu Sugiyama +7 more